Why HPLC Purity Isn't Enough for Peptide Verification

A single HPLC retention time fails to confirm the identity of a research peptide, according to a recent analysis by Oath Research. By aligning federal FDA guidance with international standards, the report establishes that reliance on standalone chromatographic results is insufficient, requiring at least two orthogonal procedures to ensure material integrity.

Corp and Tech·August 21, 2026·reads: 1,186

The convergence of requirements from the U.S. Food and Drug Administration and the U.S. Pharmacopeial Convention underscores a shift in laboratory expectations. While HPLC remains a staple for gauging purity, regulators and standard-setting bodies argue that it cannot definitively identify a substance. A 2023 paper in Pharmaceutical Research, co-authored by USP and the UK’s Medicines & Healthcare products Regulatory Agency, confirms that a single retention time lacks the specificity needed for reliable identification. The industry consensus now demands at least two orthogonal methods, such as pairing HPLC with high-resolution mass spectrometry.

For researchers sourcing peptides, this distinction is critical. A high purity percentage on a Certificate of Analysis does not guarantee the identity of the underlying compound, as a material can register clean results while remaining misidentified or degraded. Oath Research has adopted this dual-method approach, utilizing mass spectrometry alongside chromatography to bridge the gap between simple purity metrics and actual identity verification. By documenting these findings for every lot, the company aims to move beyond generic product specifications toward batch-specific transparency.